We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
DanioLabs and Senexis Announce Collaboration on Ageing Related Diseases
News

DanioLabs and Senexis Announce Collaboration on Ageing Related Diseases

DanioLabs and Senexis Announce Collaboration on Ageing Related Diseases
News

DanioLabs and Senexis Announce Collaboration on Ageing Related Diseases

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "DanioLabs and Senexis Announce Collaboration on Ageing Related Diseases"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

DanioLabs has announced the signing of a strategic collaboration with Senexis focused on discovering new treatments for ageing-related diseases.

DanioLabs has pioneered development of medium/high throughput, high content in vivo assays utilizing its cutting edge zebrafish technology. Known drugs and pharmacological probes are screened with a view to minimizing the risk of drug development. It has two programmes with positive clinical data and a strong preclinical pipeline.

DanioLabs has a major neurodegeneration programme covering Parkinson’s, Alzheimer’s and Huntington’s diseases, as well as multiple sclerosis.

Senexis is developing new chemical entities as inhibitors of amyloid-related toxicity and inflammation in Alzheimer’s disease.

Both companies expect that the combination of the two approaches will offer an opportunity to develop molecules with potential of becoming disease-modifying therapies for Alzheimer’s disease.

Paul Goldsmith, CSO of DanioLabs said: “We are excited about this collaboration because it brings Senexis’ chemistry together with our biology. It marks an important transition for us as we move from assay development and validation to the process of identifying and progressing therapeutic candidate drugs”.

"We are delighted to be collaborating with DanioLabs," commented Dr Mark Treherne, Senexis’ Chief Executive. “We look forward to a productive and fruitful collaboration”.

Advertisement